title: Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer.
abstract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the world. Traditional chemotherapy for advanced NSCLC is often considered excessively toxic. Recent clinical trials documented that gemcitabine may represent a good therapeutical option in patients with NSCLC. Aim of our research was to retrospectively evaluate the adverse effects induced by gemcitabine in patients with NSCLC from 1 January 1997 to 31 December 2002, in clinical records of Oncology Divisions of "S. Giovanni di Dio" Hospital of Crotone, "Ospedali Riuniti" Hospital of Reggio Calabria, Hospital of Paola, and in Pneumological Oncology Division of "Mariano Santo" Hospital of Cosenza, Italy. Clinical records of patients treated with gemcitabine (1000mgm(-2) on days 1 and 8) were reviewed and following data were obtained: sex and age of the patients, histologic diagnosis and disease stage, World Health Organisation (WHO) performance status and toxic effects induced by gemcitabine. We reported that 71.6% of NSCLC patients (age range 48-77 years; 135 males, 27 females; performance status 0=53, 1=109) were eligible for our study. Side effect of gemcitabine involved gastrointestinal system (nausea, vomiting and diarrhoea) and only in the last cycles (VIII-XI) emopoiethic system (leukopenia, neutropenia, thrombocytopenia and anemia). Grade IV vomiting occurred in three patients, thrombocytopenia in two. Grade III leukopenia was observed in three patients. Other toxicities were mild. None of the patients died during chemotherapy. In conclusion, these data showed that gemcitabine present a very good tolerability in patients with NSCLC. Therefore, it could be considered as a new therapeutic agents to use as first line therapy for this disease.
authors.affiliation: Chair of Pharmacology, Department of Experimental and Clinical Medicine, University of Catanzaro, Regional Pharmacovigilance Center, University of Catanzaro, Via T. Campanella 115, 88100, Catanzaro, Italy, luca_gallelli@hotmail.com
authors.forename: L
authors.initials: L
authors.lastname: Gallelli
authors.forename: M
authors.initials: M
authors.lastname: Nardi
authors.forename: T
authors.initials: T
authors.lastname: Prantera
authors.forename: S
authors.initials: S
authors.lastname: Barbera
authors.forename: M
authors.initials: M
authors.lastname: Raffaele
authors.forename: D
authors.initials: D
authors.lastname: Arminio
authors.forename: D
authors.initials: D
authors.lastname: Pirritano
authors.forename: M
authors.initials: M
authors.lastname: Colosimo
authors.forename: R
authors.initials: R
authors.lastname: Maselli
authors.forename: G
authors.initials: G
authors.lastname: Pelaia
authors.forename: P
authors.initials: P
authors.lastname: De Gregorio
authors.forename: G B
authors.initials: GB
authors.lastname: De Sarro
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy*; D016009:Chi-Square Distribution; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D000093542:Gemcitabine